G1 Therapeutics to Provide Third Quarter Corporate and Financial Update on November 5, 2019
October 29, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
September 29, 2019 06:00 ET
|
G1 Therapeutics
-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1...
G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival
September 28, 2019 04:15 ET
|
G1 Therapeutics
-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung...
G1 Therapeutics to Present New Clinical Data Across Pipeline at European Society for Medical Oncology (ESMO) 2019 Congress
September 10, 2019 06:01 ET
|
G1 Therapeutics
- Company to present first clinical data on oral SERD G1T48 in breast cancer - - Overall survival data on trilaciclib in women with metastatic triple-negative breast cancer (mTNBC) accepted for...
G1 Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference on September 9, 2019
September 03, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Financial Officer Jennifer Moses...
G1 Therapeutics Provides Second Quarter 2019 Corporate and Financial Update
August 07, 2019 16:01 ET
|
G1 Therapeutics
- FDA grants Breakthrough Therapy Designation for trilaciclib based on myelopreservation data in small cell lung cancer patients - First clinical data on oral SERD G1T48 in breast cancer to be...
G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August
August 06, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will participate in two...
G1 Therapeutics to Provide Second Quarter Corporate and Financial Update on August 7, 2019
July 31, 2019 07:00 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
G1 Therapeutics Appoints Mark Avagliano as Chief Business Officer
July 30, 2019 07:01 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointment of Mark Avagliano as Chief...
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
June 18, 2019 06:00 ET
|
G1 Therapeutics
- Detailed data from this trial will be presented at a medical meeting later this year - RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a...